Oops, looks like you need to register to access this feature.
Select “Keep Exploring” to look around Scholars in Medicine. You have full access to all videos and podcasts for a limited time. Registration is provided at no cost exclusively for healthcare providers.
Sign Up or Log In
SIM - Scholars in Medicine Logo
Login
SIM - Scholars in Medicine Logo
Founding Sponsors
Register

Cendakimab

Brand and Other Names: Cendakimab
Mechanism of Action:
Indications:
Route:
Dose:
Adverse Reactions:
Contraindication:
Warnings and Precautions:
Description:

Investigational (Phase 2–3 for eosinophilic esophagitis)

GOOGLE OVERVIEW

Target and Mechanism of Action

Cendakimab is a monoclonal antibody that specifically targets interleukin-13 (IL-13), a cytokine that plays a key role in type 2 immune responses and inflammatory processes.

  • IL-13 contributes to increased eosinophil counts, disruption of the esophageal epithelial barrier, and fibrosis—all hallmark features of eosinophilic esophagitis (EoE).

  • By blocking IL-13, Cendakimab is expected to reduce eosinophil levels and alleviate inflammation and symptoms associated with EoE.

Indication and Clinical Development

Cendakimab is being studied primarily for Eosinophilic Esophagitis (EoE)—a chronic inflammatory condition of the esophagus that often causes dysphagia and pain during swallowing.

  • Phase 3 clinical trials have shown:

    • Histological improvement: Significant reduction in eosinophil counts in the esophagus.

    • Endoscopic improvement: Reduction in visual signs of inflammation during endoscopy.

    • Symptom improvement: Including less pain and discomfort while eating.

  • Its effectiveness is particularly notable in patients who do not respond to steroid therapy, offering a promising alternative.

Potential for Other Indications

IL-13 also plays a role in various other allergic and inflammatory conditions, such as:

  • Eosinophilic asthma

  • Allergic rhinitis

  • Atopic dermatitis

This opens the possibility for Cendakimab to be further explored in treating these diseases, although its primary focus currently remains on EoE.

Regulatory and Development Status

  • Cendakimab is not yet approved by regulatory authorities such as the FDA.

  • Long-term clinical trial data (up to 48 weeks) show a consistent safety profile and tolerable side effects.

  • Developer: Bristol-Myers Squibb (BMS).

 Important Note

Cendakimab is still in the investigational stage. While the results so far are promising, it is currently only available in clinical trials and not for routine clinical use.

See package insert for full prescribing information.